Introduction
Lung cancer is the worldwide leading cause of cancer mortality (1) . Nonsmall cell lung cancer (NSCLC) patients represent the majority of lung cancer cases and they are mainly treated with standard platinum-based chemotherapy (2) . However, the poor response and a great interindividual variety in response to this chemotherapy treatment occur among these patients (3) . Thus, the reasons behind the failure and interindividual variety of response to chemotherapy and thus possibly poorer survival in these patients are very important.
The majority of lung cancer patients are smokers (4) . Cigarette smoke is known to increase the carcinogen DNA-adduct levels, which in turn form aggressive tumors by mutating and thus inactivating tumor suppressor genes, such as TP53, and thereby decrease the survival rates of patients with NSCLC (5, 6) .
Metabolic activation of N-nitrosamines such as nicotine-derived nitrosamine ketone (NNK), benzene, and vinyl chloride in cigarette smoke to mutagenic and carcinogenic metabolites are mediated by CYP2E1 (7) . In addition, CYP2E1 also plays a role in the metabolism of a number of chemotherapeutic agents and thus is involved in drug resistance (8) . The expression of CYP2E1 has also been found to be increased in lung cancer (9, 10) . The most common alleles and polymorphisms of CYP2E1 are CYP2E1*5B (RsaI/PstI C1053T/C1293C) (11, 12) and CYP2E1*6 (DraI T7632A) (13) . The variant alleles have been shown to lower activities of the corresponding enzymes (11, 12) . In addition, the CYP2E1 gene has also the CYP2E1*7B allele (14) but no information is available on its possible activity alteration. Several studies have also shown the existence of an association between lung cancer and CYP2E1*5B (15, 16) and CYP2E1*6 (13, 15) polymorphisms in various populations.
On the other hand, one of the members of glutathione S-transferase (GST) family, GST Omega 1 (GSTO1), plays a role in apoptosis (17) and is a potential reservoir of intracellular glutathione (GSH), which protects against cellular oxidative stress (18). The protective role against cell toxicity can be weakened if the enzyme activity is reduced, but the findings related to the GSTO1 gene polymorphism Ala140Asp (A140D) are still inconclusive (19, 20) . Recent studies have established an association between the GSTO1 (A140D) gene polymorphism and increased risk of several carcinomas such as breast and hepatocellular carcinoma (21) but not with lung or colorectal cancers (21, 22) .
The TP53 gene is a well-known tumor suppressor gene that regulates cell-cycle arrest, DNA repair, and apoptosis in response to cellular stress including chemotherapy (23) . Thus, normal activity of TP53 is necessary for the sensitivity of the cancer cells to chemotherapeutics and thus the inhibition of TP53 can lead to chemoresistance (24) . Tobacco-specific carcinogenic compounds have also been shown to cause mutations in the TP53 gene (25) . Several functional SNPs occur in the TP53 gene and the most frequently studied is the polymorphism TP53 (Arg72Pro), the variant allele being altered, decreasing the TP53 activity in apoptosis (26, 27) . Emerging evidence, although inconclusive, has shown that TP53 (Arg72Pro) polymorphism is not only associated with lung cancer risk but also influences patient response to platinum-based chemotherapy and survival (28) (29) (30) (31) (32) (33) . Furthermore, associations have also been shown between polymorphisms of some CYP genes such as the CYP2E1 or CYP1A1 and TP53 gene in NSCLC (5, 6, 9, 34, 35) .
All this information is necessary and important in terms of determining the predictive and prognostic significances of these genotypes of NSCLC patients, leading to the availability of the tool needed by clinicians to individualize therapies and accurately predict survival. However, a limited number of molecular epidemiological studies, with controversial results, to date have considered determining the role of CYP2E1*5B (34) (35) (36) , CYP2E1*6 (37), and TP53 (Arg72Pro) (28) (29) (30) (31) 38, 39) polymorphisms in this regard. In addition, to the best of our knowledge, no information is available with respect to CYP2E1*7B and GSTO1 (A140D) polymorphisms and their overall combined impact on clinical outcome in NSCLC.
In the present study, we aimed to determine the association either alone or in combination between the CYP2E1*5B, CYP2E1*6, CYP2E1*7B, GSTO1 (A140D), and TP53 (Arg72Pro) polymorphisms and response to platinum-based chemotherapy and survival in advanced stage NSCLC patients. Given the complexity of the pathways of drugs/pro-carcinogens and the possible interactions between encoding activation/inactivation enzymes and TP53 protein that might have cooperative impact on outcome of NSCLC patients treated with platinum-based chemotherapy, we further analyzed the possible interactions combining these gene polymorphisms with CYP1A1 (Ile462Val), CYP1B1 (Asn453Ser), GSTM1, GSTP1 (Ile105Val), GSTP1 (Ala114Val), and GSTT1 gene polymorphisms that we previously genotyped in the same patients (40).
Materials and methods

Patients
In total, 137 patients of mean age 56 ± 9 (mean ± SD; range: 34-75) who had a histological diagnosis of primary NSCLC with stages III or IV and who were treated with platinum-based chemotherapy were enrolled in this study; 125 of these patients were male, with a mean age of 56 ± 9 (mean ± SD; range: 34-75), and 12 were female, with a mean age of 58 ± 8 (mean ± SD; range: 44-69). All patients were recruited from Atatürk Pulmonary Diseases and Thoracic Surgery Hospital from February 2002 to November 2005. All patients provided written informed consent and the study was approved by the Medical Ethics Board of Atatürk Pulmonary Diseases and Thoracic Surgery Hospital. Clinical information and the chemotherapy regimen of patients and the evaluation of the effect of chemotherapy have been described in detail elsewhere (40, 41) . The responder group consisted of patients with complete response (CR) and partial response (PR) and the nonresponsive group consisted of patients with stable disease (SD) and progressive disease (PD).
Genotyping procedure
Lymphocyte DNA was isolated from the patients using a Promega genomic DNA purification kit (Promega, Madison, WI, USA) according to the manufacturer's instructions. Genetic polymorphism analyses were conducted by PCR-RFLP method. PCR master mixes were obtained from Qiagen (Hilden, Germany). Restriction enzymes were purchased from NEB (Ipswich, MA, USA). CYP2E1*5B polymorphism was determined by the method of Hayashi et al. (11) . CYP2E1*6 polymorphism was determined by the method of Kato et al. (42) . CYP2E1*7B polymorphism was determined using the method of Yang et al. (43) . Genetic polymorphism analysis for the GSTO1 (A140D) was determined by the method described by Marahatta et al. (21) . The TP53 (Arg72 Pro) gene polymorphism was determined by the method of Hu et al. (30) . For quality control, the laboratory personnel were blinded to the source of each DNA specimen and a random 10% of the samples were repeated with 100% concordance. Two authors reviewed independently 100% of the agarose gels and genotype data entry.
Statistical analysis
Chi-square analysis and Fisher's exact tests were used to compare the distribution of genotypes between subgroups and response to chemotherapy. We calculated survival as the period from diagnosis to the date of death or the date of last follow-up for each patient. Overall survival in relation to CYP, GST, and TP53 genotypes was evaluated by the Kaplan-Meier survival function and log-rank tests. Hazard ratios (HRs) were estimated from a multivariate Cox proportional hazards model with adjustment for age, sex, smoking status, chemotherapy regimen, tumor stage, and tumor histology. Only P values < 0.05 were considered significant. SPSS (SPSS, Inc., Chicago, IL, USA) was used for the statistical analysis.
Results
Characteristics of the 137 patients at diagnosis are provided in Table 1 . Among the 137 patients, 42 (31%) of them responded to the platinum-based first-line chemotherapy, whereas 95 (69%) of them did not. When the distributions of response to chemotherapy according to patient characteristics were evaluated they were not found to be related to age, sex, tumor histology, stage at diagnosis, chemotherapy regimen, or smoking status (P > 0.05, data not shown).
The distributions of the genotypes (either alone or in combination) according to patient characteristics were also evaluated and were not observed to be related to age, sex, tumor histology, stage at diagnosis, or smoking status (P > 0.05, data not shown).
Although no significant associations were noted between the gene polymorphisms alone or in combination and response to chemotherapy, patients with the TP53 The Kaplan-Meier survival functions for overall survival according to the genotypes (either alone or in combination) were analyzed. In total, 58 (42%) deaths were observed during follow-up. Among the genotypes either alone or in combination, there was no significant association between CYP2E1, GSTO1 (A140D), and TP53 genotypes and Kaplan-Meier function survival rates (P > 0.05, data not shown). We also investigated the possible interactions for combining these genes with polymorphic genes of CYPs (CYP1A1 and CYP1B1) and GSTs (GSTM1, GSTP1, and GSTT1) that we previously genotyped in these patients (40) . However, while in the previous study (40) the number of the patients was 138, in the present study the number of patients enrolled was 137. We enrolled 137 patients because one patient's DNA had run out. Therefore, we statistically recalculated the parameters of 137 patients of the previous study, excluding the patient's data whose DNA had finished. No significant associations were noted between the combined genotypes and responses to chemotherapy. However, only two of them revealed a remarkably altered survival period. The patients who had both variant genotypes of TP53 (Arg/Pro, Pro/ Pro) and CYP1A1 (Ile/Val, Val/Val) had shorter survival (median, 15.6 months) compared to those with wild-type genotypes (median, 19.4 months) (P = 0.480) (data not shown). Likewise, the patients who had variant genotypes of both TP53 (Arg/Pro, Pro/Pro) and GSTO1 (A/D, D/D) had shorter survival (median, 18.4 months) compared to those with wild-type genotypes (median, 22.7 months) (P = 0.560) (data not shown).
The distributions of CYP2E1, GSTO1, and TP53 genotypes (either alone or in combinations) and survival of the NSCLC patients are shown in Tables 3 and 4 . However, due to the very limited number of patients with null and/ or variant genotypes, only the genotype combinations that were available for statistical analysis are given in Table 4 . Overall multivariate analysis revealed no significant HR of death associated with the genotype combinations. When we analyzed the possible interactions combining these gene polymorphisms with CYP and GST gene polymorphisms that we previously genotyped in the same patients (40) , one of the genotype combinations showed a remarkably significant association with HR of death. The death risk of combined variant genotypes of TP53 (Arg/Pro, Pro/ Pro) and CYP1A1 (Ile/Val, Val/Val) increased significantly as compared to wild-type genotypes (HR, 6.03; 95% CI, 1.39-26.04, P = 0.016) ( Table 4 ). The other genotype combinations that showed remarkable but not significant increases in HR of death were CYP2E1*7B (*1A/*7B) and TP53 (Arg/Pro, Pro/Pro) (HR, 2.70; 95% CI, 0.80-9.08, P = 0.108) and GSTO1 (A/D, D/D) and TP53 (Arg/Pro, Pro/ Pro) (HR, 2.52; 95% CI, 0.75-8.49, P = 0.137).
Discussion
To the best of our knowledge this is the first study investigating the joint effect of TP53 (Arg72Pro) and the aforementioned CYP and GST polymorphisms on the clinical outcome of NSCLC patients with platinumbased chemotherapy. In the current study, we found that the TP53 Pro/Pro genotype was likely to be resistant to platinum-based chemotherapy, with marginal significance (P = 0.066), but unlikely to predict the survival. Our data also indicated that the combined polymorphisms of TP53 (Arg72Pro) and CYP1A1 (Ile 462Val) were likely to play a role in the prognosis of NSCLC patients treated with platinum-based chemotherapy.
In regard to CYP2E1 polymorphisms and survival in lung cancer, only a few studies exist and their results are rather contradictory. For example, the studies on CYP2E1*5B (37) . The CYP2E1*7B polymorphism appeared to have no effect on the prognosis of NSCLC. The studied CYP2E1 polymorphisms either alone or in combination are unlikely to a play role in the prognosis of NSCLC. The reasons for the inconsistent results of the CYP2E1*5B polymorphism on survival among these studies remain to be explored in further studies. Previous reports suggested that GSTO1 (A140D) polymorphisms might be associated with lung cancer in smokers (44, 45) . However, we could not find any association in our Turkish population (22) . In the current study, GSTO1 (A140D) polymorphism alone has been shown to have no effect on NSCLC prognosis.
The 72 Pro variant was shown to have less apoptotic potential than the 72Arg, rendering this polymorphism one of the most frequently studied variations in the P53 pathway (26, 27) . Although TP53 (Arg72Pro) polymorphism has been shown to affect the prognosis of various cancers (46, 47) , findings for NSCLC is still inconclusive and controversial (28) (29) (30) (31) 38, 39) . Our findings with respect to resistance to chemotherapy are similar to the results of the study by Han et al. (29) , who observed the variant allele was resistant to first-line chemotherapy in NSCLC. Among our nonresponsive patients carrying the 72 Pro variant allele, 3 of them were treated with platinum and etoposide and 4 of them were treated with platinum and other chemotherapeutics. In the study by Han et al. (29) , the nonresponsive patients carrying the 72 Pro variant allele were resistant to an irinotecan plus cisplatin regimen. These findings seem to reveal that this polymorphism is predictive for primary resistance especially to these chemotherapeutic drugs. With respect to overall survival our results are in line with the findings of several investigators (28) (29) (30) 38) while in contrast to those of others (31, 39) . At this stage, the reasons for the inconsistent results among all these studies, including ours, are not clear. Nevertheless, methodological and statistical discrepancies may, in part, account for the lack of consistent findings.
On the other hand, the lack of association between CYP2E1 or GSTO1 genotypes and response to chemotherapy observed in the current study is likely to show that these polymorphisms are not functioning as a predictor of response to these two distinct platinumbased chemotherapy regimens (platinum and etoposide or platinum and other chemotherapeutics).
Recent studies have demonstrated that the simultaneous analysis of such gene polymorphisms may correlate well with the clinical outcome better than the single polymorphism studies. For example, the combined variant CYP1A1 (Ile462Val) and GSTM1 null genotype was associated with better response to chemotherapy but not with survival in lung cancer (36) . Our previous study in NSCLC patients also revealed CYP1A1 and GSTP1 exon 5 variant alleles or CYP1B1 and GSTP1 exon 5 variant alleles had notable trends toward worsening of survival, whereas better survival was noted with combined GSTP1 exon 5 and GSTP1 exon 6 variant alleles (40) .
In the present study, the combined variant genotypes of TP53 (Arg/Pro, Pro/Pro) and CYP1A1 (Ile/Val, Val/ Val) were determined to play a role in the prognosis, a prognostic of worse survival, in patients with advanced (48, 49) . Positive associations have also been observed between these polymorphisms and benzo(a)pyrene 7,8-9,10 diol epoxide (BaPDE)-DNA adduct levels in the lungs of smokers or increase in cancer risk in various populations (15, 50) . Thus, the observed finding seems to be conceivable as the CYP1A1*2C gene variant elevates enzyme activity, which leads to more tobacco-specific PAH-activated carcinogenic/mutagenic e.g. BaPDE-DNA adducts, which in turn cause the formation of aggressive tumors by mutating and thus inactivating tumor suppressor gene TP53, and thereby decreasing the survival rates of patients with NSCLC. In addition, in the current study, the combined CYP2E1*7B and TP53 variant alleles and GSTO1 and TP53 variant alleles demonstrated notable trends toward worsening survival. In summary we have demonstrated that the combined variant genotypes of TP53 (Arg/Pro, Pro/Pro) and CYP1A1 (Ile/Val, Val/Val) are associated with worsening survival in advanced NSCLC patients treated with platinum-based chemotherapy. However, additional studies are required to confirm our finding.
